1. Home
  2. TSBX vs COHN Comparison

TSBX vs COHN Comparison

Compare TSBX & COHN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TSBX
  • COHN
  • Stock Information
  • Founded
  • TSBX 2015
  • COHN 1999
  • Country
  • TSBX United States
  • COHN United States
  • Employees
  • TSBX N/A
  • COHN N/A
  • Industry
  • TSBX
  • COHN Investment Bankers/Brokers/Service
  • Sector
  • TSBX
  • COHN Finance
  • Exchange
  • TSBX Nasdaq
  • COHN Nasdaq
  • Market Cap
  • TSBX 11.8M
  • COHN 16.6M
  • IPO Year
  • TSBX 2023
  • COHN N/A
  • Fundamental
  • Price
  • TSBX $0.48
  • COHN $8.60
  • Analyst Decision
  • TSBX Strong Buy
  • COHN
  • Analyst Count
  • TSBX 2
  • COHN 0
  • Target Price
  • TSBX $6.88
  • COHN N/A
  • AVG Volume (30 Days)
  • TSBX 134.2K
  • COHN 4.1K
  • Earning Date
  • TSBX 11-07-2024
  • COHN 10-31-2024
  • Dividend Yield
  • TSBX N/A
  • COHN 11.74%
  • EPS Growth
  • TSBX N/A
  • COHN N/A
  • EPS
  • TSBX N/A
  • COHN 0.83
  • Revenue
  • TSBX N/A
  • COHN $74,552,000.00
  • Revenue This Year
  • TSBX N/A
  • COHN N/A
  • Revenue Next Year
  • TSBX N/A
  • COHN N/A
  • P/E Ratio
  • TSBX N/A
  • COHN $10.30
  • Revenue Growth
  • TSBX N/A
  • COHN 21.10
  • 52 Week Low
  • TSBX $0.45
  • COHN $5.62
  • 52 Week High
  • TSBX $5.75
  • COHN $12.82
  • Technical
  • Relative Strength Index (RSI)
  • TSBX 22.35
  • COHN 50.46
  • Support Level
  • TSBX $0.45
  • COHN $8.25
  • Resistance Level
  • TSBX $0.70
  • COHN $8.70
  • Average True Range (ATR)
  • TSBX 0.05
  • COHN 0.25
  • MACD
  • TSBX 0.03
  • COHN 0.01
  • Stochastic Oscillator
  • TSBX 11.83
  • COHN 43.21

About TSBX Turnstone Biologics Corp.

Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.

About COHN Cohen & Company Inc.

Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.

Share on Social Networks: